Drugs / P-TEV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03784131 | Dec 2021 → Jun 2025 | chronic venous insufficiency | Verigraft AB | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-05-13 | Verigraft AB | Regulatory VERIGRAFT Receives CTA Approval for Phase II/III Study of P-TEV verigraft.com ↗
VERIGRAFT has received Clinical Trial Application (CTA) approval for its Phase II/III study evaluating P-TEV in patients with chronic venous insufficiency (CVI). |
| 2026-02-04 | Verigraft AB | Regulatory VERIGRAFT Q4 2025 – Clinical Milestone in Ongoing Development verigraft.com ↗
During the quarter, VERIGRAFT submitted an application to initiate a multicenter pivotal Phase II/III clinical trial (TECVI-2), evaluating the company’s patient-specific tissue therapy, the Personalized Tissue Engineered Vein (P-TEV), for patients with severe chronic venous insufficiency. |
| 2026-02-02 | Verigraft AB | Regulatory VERIGRAFT Submits Application for Pivotal Phase II/III Clinical Trial in Europe verigraft.com ↗
VERIGRAFT has submitted an application to initiate a multicenter Phase II/III clinical trial, marking an important milestone in the company’s ongoing clinical development. |
| 2025-12-03 | Verigraft AB | Results First-in-Human Results for VERIGRAFT’s Individualized Tissue-Engineered Vein (P-TEV) in Severe CVI verigraft.com ↗
The trial demonstrated very good safety outcomes and encouraging clinical improvements over a 12-month follow-up period. |
| 2025-10-29 | Verigraft AB | Results P-TEV Clinical Trial Results: VERIGRAFT Completes Phase I/II verigraft.com ↗
The P-TEV clinical trial results showed excellent safety and encouraging clinical outcomes. |
| 2025-05-27 | Verigraft AB | Regulatory Regulatory Greenlight Achieved in our Clinical Trial verigraft.com ↗
The Spanish Medicines Agency (AEMPS) has now formally approved an amendment confirming the completion of patient recruitment for the company’s ongoing Phase I/II clinical trial (TECVI-1), recognizing the strong safety profile of the P-TEV technology. |
| 2024-07-16 | Verigraft AB | Results Advancing personalized tissue therapies: VERIGRAFT P-TEV clinical trial update verigraft.com ↗ |
| 2023-07-11 | Verigraft AB | Results New Scientific Publication on VERIGRAFT P-TEV verigraft.com ↗
The work demonstrated the long-term safety and functionality of P-TEV grafts in minipigs during one year. |
| 2023-04-24 | Verigraft AB | Results Dr Lopez Espada presented data from the TECVI-1 clinical trial at ESVB in Strasbourg verigraft.com ↗
Clinical trial principal investigator Dr Christina Lopez Espada presented positive data from the TECVI-1 clinical trial at the European Symposium on Vascular Biomaterials (ESVB) 2023 in Strasbourg on April 21. |
| 2023-01-31 | Verigraft AB | Results First patient completes the TECVI-1 trial verigraft.com ↗
During one year, no safety concerns were identified, the graft was patent and the valve was functional. |
| 2022-03-02 | Verigraft AB | Results Safety assessment milestone reached in TECVI-1 clinical trial verigraft.com ↗
At the four-week visit no safety concerns were identified and the graft was patent. |
All press releases naming this drug 14 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-TEV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03784131 ↗ |
| Modality | Other / unclassified | “The advanced therapy medicinal product (ATMP) described herein is a personalized tissue- engineered vein (P-TEV) graft for use in surgical implantation to replace a defective...” NCT03784131 ↗ |
| Route | Other | “for surgical implantation” NCT03784131 ↗ |